The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: A Swedish analysis of the CREDO trial

European Journal of Health Economics

Volumn 6, Issue 4, 2005, Pages 354-362

  Ringborg, Anna ^a   Lindgren, Peter ^a   Jönsson, Bengt ^b  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Clopidogrel; Economic evaluation; Markov model; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DOSE RESPONSE; FEMALE; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; STATISTICAL MODEL; STROKE; SURVIVAL TIME; SWEDEN; TREATMENT PLANNING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SWEDEN; THROMBOSIS; TICLOPIDINE;

EID: 28844499914     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-005-0323-0     Document Type: Article

References (22)

1. Müller C, Büttner H, Petersen J et al (2000) A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 101:590-533
2. Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339:1665-1671
3. Steinhubl S, Berger P (2003) What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Am Heart J 145:971-978
4. Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 527-533
5. Steinhubl SR, Berger PB, Mann JT, 3rd et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420
6. Lindgren P, Jönsson B, Yusuf S (2004) Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden. A long-term model based on the CURE trial. J Intern Med 255:562-570
7. Lindgren R Stenestrand U, Malmberg K et al (2005) The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary interventions in Sweden. Clin Ther 27:100-110
8. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338
9. Zethraeus N, Molin T, Henriksson P et al (1999) Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 246:151-159
10. Johannesson M (2001) At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 22:919-925
11. Johannesson M (1995) The cost-effectiveness of hypertension treatment in sweden. Pharmacoeconomics 7:242-250
12. Johannesson M, Meltzer D, O'Conor RM (1997) Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 17:382-389
13. Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33-64
14. Ekman M (2001) Two essays in health economics. Consumption and production by age with emphasis on health care expenditures and economic evaluation of beta-blocker therapy in heart failure. In: Managerial Economics Section & Centre for Health Economics. Stockholm School of Economics: Stockholm
15. Burstrom K, Johannesson M, Diderichsen F (2001) Health-related quality of life by disease and socioeconomic group in the general population in Sweden. Health Policy 55:51-69
16. Läkemedelsförmånsnämnden (2003) Lä kemedelsförmånsnämnden allmänna råd om ekonomiska utvärderingar. Stockholm
17. Efron B Tibshirani R (1993) An introduction to the bootstrap. Chapman & Hall/CRC
18. Lothgren M Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623-630
19. Murray CJ, Lauer JA, Hutubessy RC et al (2003) Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361 717-725
20. Eichler H-G, Kong SX, Gerth WC et al (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 5:518-528
21. Beinart S, Kolm P, Veledar E et al (2003) Short and long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel following percutaneous coronary intervention: results from CREDO. American Heart Association: Orlando
22. Cowper PA, Udayakumar K, Sketch MH et al (2005) Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol 45:369-376